Cite
Potent, selective, and orally bioavailable matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis
MLA
Wei Li, et al. “Potent, Selective, and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitors for the Treatment of Osteoarthritis.” Bioorganic & Medicinal Chemistry, vol. 13, Dec. 2005, pp. 6629–44. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....22d053419b0d61b6ff86d04a32ae1868&authtype=sso&custid=ns315887.
APA
Wei Li, Qin Wang, Jason Shaoyun Xiang, Jeremy I. Levin, Leif M. Laakso, Xuemei Du, Thomas S. Rush, Jennifer R. Thomason, Manus Ipek, Tam Steve Yik-Kai, Yonghan Hu, Jerauld S. Skotnicki, Jean Schmid, Martin J. DiGrandi, & Jianchang Li. (2005). Potent, selective, and orally bioavailable matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis. Bioorganic & Medicinal Chemistry, 13, 6629–6644.
Chicago
Wei Li, Qin Wang, Jason Shaoyun Xiang, Jeremy I. Levin, Leif M. Laakso, Xuemei Du, Thomas S. Rush, et al. 2005. “Potent, Selective, and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitors for the Treatment of Osteoarthritis.” Bioorganic & Medicinal Chemistry 13 (December): 6629–44. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....22d053419b0d61b6ff86d04a32ae1868&authtype=sso&custid=ns315887.